Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead cMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.57
Change (%) Stock is Down 0.08 (4.85%)
Volume6,524,199
Data as of 09/23/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
09/17/14Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 CongressPrinter Friendly Version
09/08/14Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9Printer Friendly Version
09/01/14Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate CancerPrinter Friendly Version
07/31/14Exelixis Announces Second Quarter 2014 Financial ResultsPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2013 Annual Report (pdf)
Download Documentation2012 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.